Advanced maternal age, recurrent spontaneous miscarriages, repeated implantation failure
Conditions
Interventions
Control group (PGT-A group):Preimplantation genetic testing for aneuploidy based on DNA sequencing for selecting blastocysts to transfer
Experimental group (DNA and RNA sequencing group):Preimplantation screening based on DNA and RNA sequencing for selecting blastocysts to transfer
Sponsors
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Patients undergoing PGT-A treatment. Indications for PGT-A treatment include advanced maternal age (>=38 years) and/or two or more unexplained recurrent miscarriages, and/or repeated implantation failure (>=3 embryo transfers or failure after transferring 4-6 high-quality cleavage-stage embryos or >=3 high-quality blastocysts); 2.20 years old <= Age of the woman <= 40 years old; 3. On day 5 or 6 of embryo culture, obtaining 2 or more blastocysts with an inner cell mass score of B or above according to the Gardner blastocyst grading system, and a blastocyst expansion grade of 4 or higher; 4. Voluntarily agreeing to participate in this study and signing the informed consent form. If the participant is unable to read the informed consent form (e.g., illiterate participants), the informed consent process must be witnessed and signed by a witness.
Exclusion criteria
Exclusion criteria: 1. Patients with uterine cavity abnormalities, such as congenital uterine malformations (unicorunate, bicornuate, or didelphic uterus); untreated uterine septum or submucosal fibroids; or a history of moderate to severe intrauterine adhesions; 2. Untreated severe tubal hydrops with evidence of hydrosalpinx backflow into the uterine cavity; 3. Patients planning preimplantation genetic testing for structural chromosomal abnormalities (PGT-SR) or preimplantation genetic testing for monogenic disorders (PGT-M), or PGT gender selection due to Y chromosome microdeletion; 4. Patients using donor sperm or donor eggs to achieve pregnancy; 5. Untreated severe medical or surgical conditions; 6. Vulnerable populations, including individuals with mental illnesses, cognitive impairments, critically ill patients, minors, pregnant women, etc.; 7. Other situations that the researchers consider unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinica pregnancy rate after the initial embryo transfer; | — |
Secondary
| Measure | Time frame |
|---|---|
| Biochemical pregnancy rate;Implantation rate;Miscarrage rate;Birth weight;Pregnancy and perinatal complication;Live birth rate after the initial embryo transfer;Congenital anomalies; | — |
Countries
China
Contacts
Public ContactSongying Zhang
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Outcome results
None listed